Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Propose...(Lovenox(R) 201 +15.5% 39...),Health

Plavix(R) 422 +1.7% 37 +640.0% 150 +31.6%

Lantus(R) 168 +26.3% 321 +29.4% 63 +61.5%

Taxotere(R) 209 +16.8% 169 +8.3% 98 +22.5%

Eloxatin(R) 79 -36.3% 236 +12.4% 50 +19.0%

Stilnox(R)/Ambien(R)/

Ambien CR(TM)/

Myslee(R) 20 -16.7% 163 -65.8% 2 -91.3%

Copaxone(R) 84 +16.7% 188 +13.3% 8 -46.7%

Aprovel(R) 211 -0.5% - - 66 +29.4%

Tritace(R) 111 -9.8% 0 ns 84 -42.9%

Allegra(R) 8 -11.1% 74 -10.8% 66 +13.8%

Amaryl(R) 26 -23.5% 3 0.0% 72 +12.5%

Actonel(R) 51 -12.1% - - 30 +11.1%

Depakine(R) 55 +5.8% - - 25 +19.0%

Xatral(R) 41 -8.9% 28 +21.7% 15 +15.4%

Nasacort(R) 10 +11.1% 50 -3.8% 7 0.0%

Change Change Change

on a on a on a

FY 2007 comparable United comparable Other comparable

(euro million) Europe basis States basis Countries basis

Lovenox(R) 756 +9.4% 1,579 +14.8% 277 +16.9%

Plavix(R) 1,704 +5.3% 167 7.7% 553 +25.7%

Lantus(R) 627 +20.6% 1,200 +30.3% 204 +52.2%

Taxotere(R) 819 +14.5% 691 +6.5% 364 +17.0%

Eloxatin(R) 374 -33.7% 971 +9.8% 176 +11.4%

Stilnox(R)/Ambien(R)/

Ambien CR(TM)/<
'/>"/>